Silicon Canals’ Post

#Amsterdam-based Fellos, a digital men’s health clinic, has secured €2,15M in growth capital from strategic investors, including a group of healthcare professionals. Read more about it here: https://lnkd.in/grTF5mSn Sibren Tolsma, Rob Smeitink, Jeroen Bertrams, Sjoerd van Berkel, Dutch Operator Fund, Capital Mills

Amsterdam-based Fellos, a digital men’s health clinic, has secured €2,15M in growth capital from strategic investors, including a group of healthcare professionals.

Welcome to the Seedcamp Nation, Andel The US healthcare system is fragmented, often making it difficult for patients to access affordable medication. Employers can play an important role in supporting their employees by offering comprehensive pharmacy benefits. We are excited to partner with Andel from Day One and support the team on their mission to revolutionise access to critical treatments. Co-founded Ritu Malhotra, PharmD and Jay Bregman - an experienced duo that combines business savvy with a first-hand understanding of the US healthcare ecosystem - Andel offers a unique cooperative model that leverages members’ combined buying power to purchase medications directly from manufacturers at below-market prices. Employers can add a subsidy of their choosing to reduce costs to members even further. Andel’s native app provides a seamless experience from prescription verification to next‑day delivery. Employees obtain the brand-name medicine they need at a price they can afford, without having to wait for approvals or prerequisites. Ritu Malhotra, co-founder of Andel and a licensed pharmacist, highlights: “Expanding access to healthcare is the cornerstone of our mission. Andel gives employers an innovative new pharmacy benefit solution that fills the coverage gap.” We are thrilled to participate in Andel’s $4.5 million funding round alongside Lightbank, Bertelsmann Investments, Houghton Street Ventures, Springboard Enterprises, SemperVirens Venture Capital and City Light Capital. Andel is launching US-wide in early 2026. Read more below.

Super glad to share that Seedcamp has backed Andel, co-founded by Jay Bregman and Ritu Malhotra. Together, they are taking on one of U.S. healthcare’s most pressing challenges: how to make vital, high-cost medications increasingly accessible to those who need them. By giving employers a new way to offer branded medications like GLP-1s through pooled purchasing and direct manufacturer partnerships, Andel isn’t just improving benefits. It’s changing the way the system pays for and provides access to vital medicines. Jay and Ritu’s expertise in entrepreneurship and healthcare make them uniquely positioned to lead this transformation. Looking forward to seeing Andel scale to launch nationwide in 2026.

The Frist Cressey Ventures team is thrilled to share that our portfolio company Visana Health has raised $24M in Series A Funding! “The reality is that many women in the workforce are silently managing multiple chronic conditions – the average Visana patient has 3 to 4. By not addressing this, employers carry unnecessary costs,” said Joe Connolly, Co-founder and CEO of Visana Health. “This financing is a recognition of the extraordinary progress we’ve made since our seed round– scaling nationwide to all 50 states, expanding our clinical scope, and proving that women’s healthcare can deliver both outstanding outcomes and actuarily-verified cost savings at scale.” We're thrilled to partner once again with the #VisanaHealth team to transform women's healthcare! Led by Noro-Moseley Partners with support from The Cigna Group Ventures, Intermountain Ventures, and backing from existing investors at Flare Capital Partners and FCV, this fundraise fuels Visana's expansion into weight loss, cardiometabolic care and chronic condition management, and expansion of its AI capabilities. https://lnkd.in/djQzmsd7

Excited to welcome Noro-Moseley Partners, The Cigna Group Ventures and Intermountain Ventures to the Visana Health team! Spence McClelland, Thomas Collier, Rachel Anderson, Tom Olenzak, Dakota Hansen, Nickolas Mark ...and to continue working with my partners in crime (or VC?) Margaret Malone, Victor Lanio, Mike Tudeen, Lavanya Bhamidipati, Jenni Le, Tommaso Auerbach. When I met co-founders Joe Connolly and Shelly Lanning in early 2023 I had the beautiful and rare "this is exactly what we've been looking for" moment. Our healthcare system is built on siloed interactions, specialties and payments. This is not how women's *health* works. Half of our population is clinically predisposed to specific overlapping diseases without a comprehensive and coordinated clinical model, and the archaic benefit design [absolutely not designed with women in mind] means women spend 20% more out of pocket, or $154B! Women end up cycling aimlessly throughout the system (10% higher care utilization), paying more without actual resolution, or some skip care altogether until they become ultra high acuity and require surgery or specialty Rx. 45%+ of women will have a gynecologic surgery in their life, 75% of these are avoidable. Which means health plans and employers also shoulder this cost and are looking to do something about it. It's not just surgery though, 15% of overall commercial plan spend is driven by members with at least one complex GYN condition. (the average Visana patient manages 3.6 chronic conditions) Just ask Barbara Levy, MD, FACOG, FACS, our Visana CMO. When she's not on Capitol Hill presenting the right clinical model or payment structure for women's health, she's building our clinical quality models and training our new cohorts of Visana clinicians to make sure we can transform the experience for patients to become coordinated and outcomes-focused. If higher acuity care is needed, we can get them to the appropriate sites fast (no six month waiting lists). Chevon Rariy, MD, our Visana Chief Clinical Innovation Officer, is expanding Visana's reach to make sure we can care for all needs including cardiometabolic, behavioral and more. We can't service women appropriately in the right clinical model if we can't take care of all their needs, for all ages 18-65 years. For example, the industry loves talking about menopause right now which is fantastic, there is so much need. However, I don't hear the full issues talked about enough. Menopause is a time when women face their greatest acceleration in cardiometabolic risk, we can't build a clinical model without addressing that too. Cost - last but certainly not least. Actuarial analysis demonstrates that Visana reduces medical spend by 34%, cuts unnecessary procedures by 78%, and delivers more than $2,400 in annual savings per enrollee. Get in touch, we will building out the Visana Health team with this capital and running at the huge opportunity in front of us. Congratulations team!

We love closing the week with this news: LillianCare raises new funding to scale its hybrid primary care model across rural Germany! We’re proud to continue supporting LillianCare alongside amberra, Nina Capital, Calm/Storm, caesar., Venture League, and happy to welcome Creas and BONVENTURE as new investors! Founded in 2023, LillianCare is addressing one of Germany’s most pressing healthcare challenges, the shortage of general practitioners, by bringing modern, patient-centered care to rural areas. Its hybrid model combines interdisciplinary medical teams on-site with digital solutions such as telemedicine. With five practices already operating in Rhineland-Palatinate and Lower Saxony, the company plans to expand to 400 practices by 2030, closing critical gaps in access to healthcare. Patients gain faster access to medical care nearby, while doctors benefit from more flexible working models. “The fact that we were able to attract additional investors who share our vision is a strong signal for us,” said Linus Drop, Co-CEO and Co-Founder of LillianCare. “Trust, proximity, reliability, these shared values perfectly align with our mission to make primary care future-proof. We’re also very pleased that our existing investors continue to back us strongly.” We have made this investment through BSocial Impact Fund, supported by Banco Sabadell, European Investment Fund (EIF), and AXIS, among other investors.

🩺 The UK Government has made reducing elective care waiting times a key priority, and while progress has been made with the overall waiting list falling from 7.6 to 7.4 million, the NHS remains under significant pressure. To make the health system fit for the future, there is an urgent need to accelerate the adoption of proven innovations that improve access, outcomes and efficiency. We recently partnered with Meridian Health Ventures (MHV) to invest in the first NHS-anchored venture fund backing UK HealthTech companies, with the aim of improving population health, reducing the cost of care and advancing health equity. 🌱 The Fund will invest in digital health, enterprise healthcare and MedTech companies providing solutions with clear potential to scale within the NHS. It also offers hands-on support to the ventures it backs, connecting them to key NHS stakeholders, guiding the development of robust evidence for innovations and facilitating links across UK and US health systems. 👉 To know more, visit: https://lnkd.in/egaeVFZ9

WellTheory raises $14M Series A to scale whole-person autoimmune care WellTheory, a San Francisco-based virtual care platform for autoimmune disease, has raised $14 million in Series A funding, bringing its total funding to $26.2 million. The round was led by General Catalyst, with participation from 7wire Ventures, Ingeborg Investments, Accel, Box Group, Leaps by Bayer, and Up2 Opportunity Fund. Candace Richardson, Partner at General Catalyst, will join WellTheory’s board. Founded and led by CEO Ellen Rudolph, WellTheory delivers whole-person, evidence-based care that addresses the root causes of autoimmunity—helping members reduce symptoms, improve quality of life, and lower overall healthcare costs. Its interdisciplinary care team includes registered dietitians and board-certified health coaches, powered by AI-enabled personalization to tailor support at every stage. In just 18 months on the commercial market, WellTheory has built partnerships with Fortune 100 and 500 employers and leading organizations such as Maven Clinic, Fortune Brands Innovations, Dayforce, and payors like Sentara Health Plans and a top national insurer. The new funding will fuel deeper partnerships with employers and payors, expand targeted care programs, and advance its personalization technology to make autoimmune care more accessible and effective. 🌿 A big step forward for patient-centered, preventive autoimmune care. #WellTheory #HealthTech #AutoimmuneCare #WholePersonCare #VirtualCare #DigitalHealth #AIinHealthcare #FundingNews #GeneralCatalyst #7wireVentures #LeapsByBayer #HealthcareInnovation #SeriesAFunding #ChronicCare #PatientExperience

"Strasbourg-based RDS, a French MedTech company, today announced a €14 million Series A funding round for its remote monitoring and wearable patch"